Chemotherapy for Good-Risk Germ Cell Tumors: Current Concepts and Controversies

Urologic Clinics of North America

Volumn 34, Issue 2, 2007, Pages 171-177

  Vaughn, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; GERM CELL TUMOR; GLOMERULAR DYSFUNCTION; HEARING LOSS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; ISCHEMIC HEART DISEASE; LUNG TOXICITY; METABOLIC SYNDROME X; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; STATISTICAL ANALYSIS; TINNITUS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 34247604927     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.03.001     Document Type: Review

References (31)

1. American Cancer Society. Cancer Facts and figures, 2007 (2007), American Cancer Society, Atlanta
2. Birch R., Williams S., Cone A., et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4 (1986) 400-407
3. Bosl G.J., Geller N.L., Cirrincione C., et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43 (1983) 3403-3407
4. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15 (1997) 594-603
5. Einhorn L.H., Williams S.D., Loehrer P.J., et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group Protocol. J Clin Oncol 7 (1989) 387-391
6. Saxman S.B., Finch D., Gonin R., et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ cell tumors: the Indiana University experience. J Clin Oncol 16 (1998) 702-706
7. De Wit R., Roberts J.T., Wilkinson P.M., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for the Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19 (2001) 1629-1640
8. Sleijfer S. Bleomycin-induced pneumonitis. Chest 120 (2001) 617-624
9. O'Sullivan J.M., Huddart R.A., Norman A.R., et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14 (2003) 91-96
10. Loehrer P.J., Johnson D., Elson P., et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 13 (1995) 470-476
11. deWit R., Stoter G., Kaye S.B., et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized trial of the European Organization for the Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15 (1997) 1837-1843
12. Bosl G.J., Geller N.L., Bajorin D., et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6 (1988) 1231-1238
13. Kondagunta G.V., Bacik J., Bajorin D., et al. Etoposide and cisplatin for metastatic good-risk germ cell tumors. J Clin Oncol 23 (2005) 9290-9294
14. Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11 (1993) 598-606
15. Horwich A., Sleijfer D.T., Fossa S.D., et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for the Research and Treatment of Cancer Trial. J Clin Oncol 15 (1997) 1844-1855
16. Culine S., Kerbrat P., Bouzy J., et al. The optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ cell tumors (MNSGCT) is 3 cycles of bleomycin, etoposide, and cisplatin: mature results of a randomized trial. [abstract # 1536]. Proc Amer Soc Clin Oncol 22 (2003) 383
17. Motzer RJ, Bolger GB, Boston B, et al. Testicular cancer. J Natl Compr Canc Netw 2006;4(10):1038-58. Available at: http://www.nccn.org/professionals/physician_gls/PDF/testicular.pdf.
18. Schmoll H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Annals of Oncology 15 (2004) 1377-1399
19. Vaughn D.J., Gignac G.A., and Meadows A.T. Long-term medical care of testicular cancer survivors. Ann Intern Med 136 6 (2002) 463-470
20. Vogelzang N.J., Bosl G.J., Johnson K., et al. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95 (1981) 288-292
21. Vogelzang N.J., Frenning D.H., and Kennedy B.J. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep 64 (1980) 1159-1160
22. Doll D.C., List A.F., Greco F.A., et al. Acute vascular ischemic events after cisplatin-related combination chemotherapy for germ cell tumors of the testis. Ann Intern Med 105 (1986) 48-51
23. Lederman G.S., and Garnick M.B. Pulmonary emboli as a complication of germ cell cancer treatment. J Urol 137 (1987) 1236-1237
24. Nichols C.R., Roth B.J., Williams S.D., et al. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 10 (1992) 760-765
25. Meinardi M.T., Gietema J., Van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18 (2000) 1725-1732
26. Huddart R.A., Norman M., Shahidi M., et al. Cardiovascular disease as a long term complication of treatment for testicular cancer. J Clin Oncol 21 (2003) 1513-1523
27. van den Belt-Dusebout A.W., Nuver J., deWit R., et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 20 (2006) 467-475
28. Nuver J., Smit A.J., Wolffenbuttel B.H., et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23 (2005) 3718-3725
29. Sagstuen H., Aass N., Fossa S.D., et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 23 (2005) 4980-4990
30. Bokemeyer C., and Schmoll H.J. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13 (1995) 283-292
31. Travis L.B., Fossa S.D., Schonfeld S.J., et al. Second cancers among 40576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97 (2005) 1361-1365